Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
INFECTIOUS DISEASE AND IMMUNOLOGY: IMMUNODEFICIENCY DISEASES

CORRECTION OF ADA-SCID BY STEM CELL GENE THERAPY COMBINED WITH NONMYELOABLATIVE CONDITIONING

Scott H. Sicherer
Pediatrics August 2003, 112 (Supplement 2) 489-490;
Scott H. Sicherer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF

Aiuti A, Slavin S, Aker M, et al. Science. 2002;296:2410–2413

Purpose of the Study.

To use improved gene therapy techniques to correct adenoside deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

Patient Population.

Two patients (7 months old and 2.5 years) with ADA-SCID who lacked an HLA-identical sibling donor and for whom polyethylene glycol conjugated (PEG)-ADA was unavailable.

Methods.

Patients underwent collection of autologous CD34+ cells (stem cells) from bone marrow that were corrected for ADA by transduction using a retroviral vector and infused 4 days later. Patients received nonmyeloablative treatment with busulfan.

Results.

Both patients experienced immune reconstitution (although the infant showed a swifter and more complete response). Genetically corrected granulocytes, monocytes, megakaryocytes, and erythroid cells were detected, T cell responses normalized, antibody production was corrected, and specific responses to vaccination were documented. Infections also abated. Red blood cell toxic metabolites declined and liver enzyme abnormalities resolved. The less complete response of the older patient was attributed to a lower dose of transfected cells, less myeloablation, and possibly an effect of his older age.

Conclusions.

A combined approach of using autologous genetically corrected stem cells and nonmyeloablative conditioning allowed more complete restoration of immune and metabolic functioning in ADA-SCID patients than has been previously achieved.

Reviewer’s Comments.

ADA leads to the accumulation of toxic metabolites that cause immune cell death and results in SCID. Previous studies of therapy using genetically corrected peripheral blood lymphocytes (PBLs) and exogenous ADA in the form of PEG-ADA to support immune function lead to poor engraftment of the corrected cells possibly because there was not a sufficient survival advantage for these cells in the presence of exogenous ADA. When PEG-ADA was not given, full correction was still not achieved, indicating that such correction may require a more global therapy, not just infusion of genetically corrected PBLs. This study shows that rather amazing immune reconstitution was possible with the successful engraftment of multipotent, genetically corrected stem cells, and provides hope for more definitive therapy for this and other disorders.

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 112, Issue Supplement 2
1 Aug 2003
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
CORRECTION OF ADA-SCID BY STEM CELL GENE THERAPY COMBINED WITH NONMYELOABLATIVE CONDITIONING
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
CORRECTION OF ADA-SCID BY STEM CELL GENE THERAPY COMBINED WITH NONMYELOABLATIVE CONDITIONING
Scott H. Sicherer
Pediatrics Aug 2003, 112 (Supplement 2) 489-490;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
CORRECTION OF ADA-SCID BY STEM CELL GENE THERAPY COMBINED WITH NONMYELOABLATIVE CONDITIONING
Scott H. Sicherer
Pediatrics Aug 2003, 112 (Supplement 2) 489-490;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Purpose of the Study.
    • Patient Population.
    • Methods.
    • Results.
    • Conclusions.
    • Reviewer’s Comments.
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

INFECTIOUS DISEASE AND IMMUNOLOGY: IMMUNODEFICIENCY DISEASES

  • THE AMOUNT OF SCURFIN PROTEIN DETERMINES PERIPHERAL T CELL NUMBER AND RESPONSIVENESS
  • SEVERITY OF MENINGOCOCCAL DISEASE IN CHILDREN AND THE ANGIOTENSIN-CONVERTING ENZYME INSERTION/DELETION POLYMORPHISM
  • ANTIBODY DEFICIENCY AND AUTOIMMUNITY IN 22q11.2 DELETION SYNDROME
Show more INFECTIOUS DISEASE AND IMMUNOLOGY: IMMUNODEFICIENCY DISEASES

ABSTRACTS

  • THE AMOUNT OF SCURFIN PROTEIN DETERMINES PERIPHERAL T CELL NUMBER AND RESPONSIVENESS
  • SEVERITY OF MENINGOCOCCAL DISEASE IN CHILDREN AND THE ANGIOTENSIN-CONVERTING ENZYME INSERTION/DELETION POLYMORPHISM
  • ANTIBODY DEFICIENCY AND AUTOIMMUNITY IN 22q11.2 DELETION SYNDROME
Show more ABSTRACTS

Similar Articles

Subjects

  • Infectious Disease
    • Infectious Disease
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics